Epidermal growth factor receptor tyrosine kinase (EGFR-TK, PDB ID: 1M17) was selected for prodigiosin’s anticancer potential against skin cancer, aiming to disrupt uncontrolled cell growth [33]. Here, TKT is linked to skin neoplasm.